MannKind Q2 total revenues $49M (+157% YoY); Tyvaso DPI royalties $19M (+63% QoQ)

MANNKIND CORP

2023-Q2 EPS reported -$0.06 revenue$89,237,000

Tyvaso DPI royalties $19M in Q2, up 63% from Q1, driven by strong patient demand.
Afrezza net revenue $13.5M, up 27% YoY due to higher demand and price.
GAAP income from operations $2M; non-GAAP income from operations $8M.
Total revenues H1 2023 $89.2M, +189% vs H1 2022.
Cash and investments $146.6M as of June 30, 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

MANNKIND CORP reported quarter ended June 30, 2023 results: revenue $48,611.

Period: quarter ended June 30, 2023
Revenue: $48,611
Result: reported results

Exact text from the filing

27 % Net revenue – V-Go 4,818 2,073 $ 2,745 * Revenue – collaborations and services 11,211 5,868 $ 5,343 91 % Royalties – collaborations 19,055 304 $ 18,751 * Total revenues $ 48,611 $ 18,894 $ 29,717 157 % ________________________ * Not meaningful Afrezza net revenue for the second quarter of 2023 increased $2.9 million, or 27%, compared to the same period in

View on SEC.gov

Browse all earnings releases →

MANNKIND CORP filing history →

Source: SEC EDGAR

accession 0000950170-23-039048

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.